|
|
 |
|
Viewing report
|
|
|
|
The CRO Market Outlook: Emerging Markets, Leading Players and Future Trends
Business Insights, Aug 2009, Pages: 167
Rising costs and falling productivity, among other trends are driving pharmaceutical companies to outsource an increasing range of functions to CROs in search of time and cost savings. This produced strong double-digit growth in the sector between 2003 and 2008. However, amongst other resistors, the financial crisis resulted in reduced funding available for biotech companies. This fully updated CRO Market Outlook assesses the market drivers and resistors and predicts the effects of these. The report analyzes the overarching trends in the industry; examines which regions are set to see growth in CRO activity; evaluates the leading CROs; and outlines the future of the industry. The report provides insight into conditions into seven emerging regions including China, India and Latin America. It highlights the evolving business and relationship models between CROs and sponsor companies and enables optimal outsourcing strategy.
Key features of this report
- Identifies and analyses the most recent trends and issues in outsourcing clinical R&D
- Describes where clinical trials will be conducted in the future
- Explores the complexities and the costs of outsourcing R&D to different world regions
- Profiles the major international CRO players
- Provides a detailed assessment of the current CRO market including market share information and the size/growth of R&D spending
- Focuses on emerging CRO markets
- Highlights evolving strategies for working with CROs
- Examines existing and future CRO business models
Key findings from this report
- The total CRO market size is estimated at $20bn in 2008 and expected to grow at an annual rate of 8.5% to reach $35bn through 2015. The market is highly fragmented and the number of CROs worldwide has reached over 1,100 despite continued consolidation.
- CROs provide substantial global capacity to drug developers and have become a critical contributor to clinical trial activity. Clinical trials conducted by CROs are completed up to 30% more quickly than those conducted in-house by pharma companies.
- Of the large, global contract research providers, Quintiles is market leader, with 15% of the global market share, followed by Covance and PPD. The five largest CROs have increased their market share and now hold 55% of the total market.
- The leading CROs are commodity full service providers operating on a global scale. They act as one-stop shops for all services, from preclinical through marketing.
- The number of clinical studies conducted in Asia, Central and Eastern Europe and Latin America is constantly rising. India and China are the future outsourcing destinations of choice.
- CROs and pharmaceutical companies are turning to strategic partnerships to gain a competitive edge in the global business environment.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Contract Research Outsourcing (CRO) - A Global Update of Market Trends & Opportunities
Global CRO Spending Trends
2008 Report for the Investigation of the Chinese Medical and Pharmaceutical CRO Market
Strategies for Innovation in Pharmaceutical R&D: Enhancing R&D Through Biotech Alliances and CRO Outsourcing
Pharmaceutical Outsourcing Strategies: Market Expansion, Offshoring and Strategic Management in the CRO and CMO Marketplace
European CRO Markets - A Strategic Analysis
Strategic Analysis of Opportunities in the CRO Market - Phase 0
China Contract Research Organization (CRO) Market
2009 CRO Quality Benchmarking Study - CRO Selection for Biotechnology Companies
Outsourcing Clinical Trials: A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index
200 China-based Best CROs and CMOs
China Pharma Outsourcing Market By 2015
|
|
|
|
